RESUMO
Background: Human immunodeficiency virus (HIV)-infected individuals are at increased risk of age-associated functional impairment, even with effective antiretroviral therapy (ART). A concurrent characterization of skeletal muscle, physical function, and immune phenotype in aviremic middle-aged HIV-infected adults represents a knowledge gap in prognostic biomarker discovery. Methods: We undertook a prospective observational study of 170 middle-aged, HIV-infected ambulatory men and women with CD4+ T-cell counts of at least 350/µL and undetectable plasma viremia while on effective ART, and uninfected control participants. We measured biomarkers for inflammation and immune activation, fatigue, the Veterans Aging Cohort Study mortality index, and physical function. A subset also received a skeletal muscle biopsy and computed tomography scan. Results: Compared to the uninfected participants, HIV-infected participants displayed increased immune activation (P < .001), inflammation (P = .001), and fatigue (P = .010), and in a regression model adjusting for age and sex displayed deficits in stair-climb power (P < .001), gait speed (P = .036), and predicted metabolic equivalents (P = .019). Skeletal muscle displayed reduced nuclear peroxisome proliferator-activated receptor-γ coactivator 1α-positive myonuclei (P = .006), and increased internalized myonuclei (P < .001) that correlated with immune activation (P = .003) and leukocyte infiltration (P < .001). Internalized myonuclei improved a model for HIV discrimination, increasing the C-statistic from 0.84 to 0.90. Conclusions: Asymptomatic HIV-infected middle-aged adults display atypical skeletal muscle profiles, subclinical deficits in physical function, and persistent inflammation and immune activation. Identifying biomarker profiles for muscle dysregulation and risk for future functional decline in the HIV-infected population will be key to developing and monitoring preventive interventions. Clinical Trials Registration: NCT03011957.
Assuntos
Infecções Assintomáticas , Infecções por HIV/complicações , Inflamação , Músculo Esquelético/patologia , Idoso , Biomarcadores , Biópsia , Fadiga/etiologia , Fadiga/virologia , Feminino , HIV/isolamento & purificação , Infecções por HIV/imunologia , Humanos , Masculino , Pessoa de Meia-Idade , Músculo Esquelético/virologia , Coativador 1-alfa do Receptor gama Ativado por Proliferador de Peroxissomo/análise , Estudos Prospectivos , Linfócitos T/imunologia , Viremia , Velocidade de CaminhadaRESUMO
Context: Testosterone increases skeletal muscle mass and strength, but long-term effects of testosterone supplementation on aerobic capacity, or peak oxygen uptake (VÌO2peak), in healthy older men with low testosterone have not been evaluated. Objective: To determine the effects of testosterone supplementation on VÌO2peak during incremental cycle ergometry. Design: A double-blind, randomized, placebo-controlled, parallel-group trial (Testosterone's Effects on Atherosclerosis Progression in Aging Men). Setting: Exercise physiology laboratory. Participants: Healthy men aged ≥ 60 years with total testosterone levels of 100 to 400 ng/dL (3.5 to 13.9 nmol/L) or free testosterone levels < 50 pg/mL (174 pmol/L). Interventions: Randomization to 1% transdermal testosterone gel adjusted to achieve serum levels of 500 to 950 ng/dL or placebo applied daily for 3 years. Main Outcome Measures: Change in VÌO2peak. Results: Mean (±SD) baseline VÌO2peak was 24.2 ± 5.2 and 23.6 ± 5.6 mL/kg/min for testosterone and placebo, respectively. VÌO2peak did not change in men treated with testosterone but fell significantly in men receiving placebo (average 3-year decrease, 0.88 mL/kg/min; 95% CI, -1.39 to 0.38 mL/kg/min; P = 0.035); the difference in change in VÌO2peak between groups was significant (average 3-year difference, 0.91 mL/kg/min; 95% CI, 0.010 to 0.122 mL/kg/min; P = 0.008). The 1-g/dL mean increase in hemoglobin (P < 0.001) was significantly associated with changes in VÌO2peak in testosterone-treated men. Conclusion: The mean 3-year change in VÌO2peak was significantly smaller in men treated with testosterone than in men receiving placebo and was associated with increases in hemoglobin. The difference in VÌO2peak change between groups may indicate attenuation of its expected age-related decline; the clinical meaningfulness of the modest treatment effect remains to be determined.
Assuntos
Envelhecimento/metabolismo , Aterosclerose/patologia , Hipogonadismo/tratamento farmacológico , Pulmão/efeitos dos fármacos , Consumo de Oxigênio/efeitos dos fármacos , Testosterona/uso terapêutico , Idoso , Envelhecimento/sangue , Envelhecimento/efeitos dos fármacos , Aterosclerose/complicações , Aterosclerose/fisiopatologia , Composição Corporal/efeitos dos fármacos , Composição Corporal/fisiologia , Progressão da Doença , Método Duplo-Cego , Terapia de Reposição Hormonal , Humanos , Hipogonadismo/complicações , Hipogonadismo/metabolismo , Hipogonadismo/fisiopatologia , Pulmão/fisiologia , Medidas de Volume Pulmonar , Masculino , Pessoa de Meia-Idade , Músculo Esquelético/efeitos dos fármacos , Placebos , Fatores de TempoRESUMO
Importance: The Institute of Medicine set the recommended dietary allowance (RDA) for protein at 0.8 g/kg/d for the entire adult population. It remains controversial whether protein intake greater than the RDA is needed to maintain protein anabolism in older adults. Objective: To investigate whether increasing protein intake to 1.3 g/kg/d in older adults with physical function limitations and usual protein intake within the RDA improves lean body mass (LBM), muscle performance, physical function, fatigue, and well-being and augments LBM response to a muscle anabolic drug. Design, Setting, and Participants: This randomized clinical trial with a 2 × 2 factorial design was conducted in a research center. A modified intent-to-treat analytic strategy was used. Participants were 92 functionally limited men 65 years or older with usual protein intake less thanor equal to 0.83 g/kg/d within the RDA. The first participant was randomized on September 21, 2011, and the last participant completed the study on January 19, 2017. Interventions: Participants were randomized for 6 months to controlled diets with 0.8 g/kg/d of protein plus placebo, 1.3 g/kg/d of protein plus placebo, 0.8 g/kg/d of protein plus testosterone enanthate (100 mg weekly), or 1.3 g/kg/d of protein plus testosterone. Prespecified energy and protein contents were provided through custom-prepared meals and supplements. Main Outcomes and Measures: The primary outcome was change in LBM. Secondary outcomes were muscle strength, power, physical function, health-related quality of life, fatigue, affect balance, and well-being. Results: Among 92 men (mean [SD] age, 73.0 [5.8] years), the 4 study groups did not differ in baseline characteristics. Changes from baseline in LBM (0.31 kg; 95% CI, -0.46 to 1.08 kg; P = .43) and appendicular (0.04 kg; 95% CI, -0.48 to 0.55 kg; P = .89) and trunk (0.24 kg; 95% CI, -0.17 to 0.66 kg; P = .24) lean mass, as well as muscle strength and power, walking speed and stair-climbing power, health-related quality of life, fatigue, and well-being, did not differ between men assigned to 0.8 vs 1.3 g/kg/d of protein regardless of whether they received testosterone or placebo. Fat mass decreased in participants given higher protein but did not change in those given the RDA: between-group differences were significant (difference, -1.12 kg; 95% CI, -2.04 to -0.21; P = .02). Conclusions and Relevance: Protein intake exceeding the RDA did not increase LBM, muscle performance, physical function, or well-being measures or augment anabolic response to testosterone in older men with physical function limitations whose usual protein intakes were within the RDA. The RDA for protein is sufficient to maintain LBM, and protein intake exceeding the RDA does not promote LBM accretion or augment anabolic response to testosterone. Trial Registration: clinicaltrials.gov Identifier: NCT01275365.
Assuntos
Atividades Cotidianas , Composição Corporal , Proteínas Alimentares/administração & dosagem , Nível de Saúde , Saúde Mental , Força Muscular , Qualidade de Vida , Absorciometria de Fóton , Afeto , Idoso , Idoso de 80 Anos ou mais , Androgênios/uso terapêutico , Método Duplo-Cego , Fadiga , Humanos , Vida Independente , Masculino , Recomendações Nutricionais , Testosterona/análogos & derivados , Testosterona/uso terapêuticoRESUMO
The dietary protein allowance for older men to maintain lean body mass and muscle strength and to accrue optimal anabolic responses to promyogenic stimuli is poorly characterized. The OPTIMEN trial was designed to assess in older men with moderate physical dysfunction and insufficient habitual protein intake (Assuntos
Androgênios/farmacologia
, Composição Corporal/fisiologia
, Proteínas Alimentares/administração & dosagem
, Força Muscular/fisiologia
, Músculo Esquelético/metabolismo
, Testosterona/análogos & derivados
, Absorciometria de Fóton
, Idoso
, Índice de Massa Corporal
, Método Duplo-Cego
, Ingestão de Energia
, Humanos
, Masculino
, Projetos de Pesquisa
, Testosterona/farmacologia
RESUMO
CONTEXT: Testosterone increases skeletal muscle mass and strength, but the effects of testosterone on aerobic performance in mobility-limited older men have not been evaluated. OBJECTIVE: To determine the effects of testosterone supplementation on aerobic performance, assessed as peak oxygen uptake (VÌO2peak) and gas exchange lactate threshold (VÌO2θ), during symptom-limited incremental cycle ergometer exercise. DESIGN: Subgroup analysis of the Testosterone in Older Men with Mobility Limitations Trial. SETTING: Exercise physiology laboratory in an academic medical center. PARTICIPANTS: Sixty-four mobility-limited men 65 years or older with low total (100-350 ng/dL) or free (<50 pg/dL) testosterone. INTERVENTIONS: Participants were randomized to receive 100-mg testosterone gel or placebo gel daily for 6 months. MAIN OUTCOME MEASURES: VÌO2peak and VÌO2θ from a symptom-limited cycle exercise test. RESULTS: Mean (SD) baseline VÌO2peak was 20.5 (4.3) and 19.9 (4.7) mL/kg/min for testosterone and placebo, respectively. VÌO2peak increased by 0.83 (2.4) mL/kg/min in testosterone but decreased by -0.89 (2.5) mL/kg/min in placebo (P = .035); between group difference in change in VÌO2peak was significant (P = .006). This 6-month reduction in placebo was greater than the expected -0.4-mL/kg/min/y rate of decline in the general population. VÌO2θ did not change significantly in testosterone but decreased by 1.1 (1.8) mL/kg/min in placebo, P = .011 for between-group comparisons. Hemoglobin increased by 1.0 ± 3.5 and 0.1 ± 0.8 g/dL in testosterone and placebo groups, respectively. CONCLUSION: Testosterone supplementation in mobility-limited older men increased hemoglobin and attenuated the age-related declines in VÌO2peak and VÌO2θ. Long-term intervention studies are needed to determine the durability of this effect.